<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;F11&lt;/i&gt; (gene for coagulation factor XI)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>F11</i> (gene for coagulation factor XI)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>F11</i> (gene for coagulation factor XI)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy D Shapiro, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Meadow Heiman, MS, LCGC, CCRC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James L Zehnder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1441418377"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the implications of results from germline testing of the<em> F11</em> gene, which encodes coagulation factor XI (FXI). </p><p>FXI circulates as an inactive form (zymogen) and becomes activated to FXIa, an enzyme that amplifies clotting and reduces clot breakdown (fibrinolysis), especially at sites of injury  (<a class="graphic graphic_figure graphicRef79998" href="/z/d/graphic/79998.html" rel="external">figure 1</a>).</p><p>Most commonly, pathogenic variants in the <em>F11</em> gene result in a decreased factor XI level and possible bleeding symptoms. Individuals with FXI deficiency can have a bleeding disorder of variable severity. They require comprehensive management, best guided by consultation with a federally recognized hemophilia treatment center (HTC) or another center of excellence. </p><p>The general approach to evaluating bleeding disorders and detailed information about FXI deficiency and other specific coagulation factor deficiencies are discussed separately in UpToDate [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2100297814"><span class="h1">ASSESSMENT</span></p><p class="headingAnchor" id="H2486342573"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>Before acting on the results, confirm that the correct gene was tested and the test was performed in a clinical laboratory improvements amendment (CLIA)-certified laboratory. The table lists other caveats  (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>). </p><p>Coagulation factors are numbered using Roman numerals; gene names use Arabic numerals. Transposition of Roman numerals can result in ordering or testing the incorrect factor activity levels. Confirm that the correct/intended factor gene and factor activity were tested and correlated.</p><p>Assess the technology that was used to perform the testing. Some laboratories only test for common variants in <em>F11</em>; however, laboratories are increasingly using next generation sequencing (NGS), which detects a wider range of variants. This may help identify whether further genetic testing is warranted.</p><p>Not all variants cause a clinical disorder  (<a class="graphic graphic_table graphicRef122646" href="/z/d/graphic/122646.html" rel="external">table 2</a>). Pathogenic and likely pathogenic <em>F11</em> variants (and some variants labeled as variants of uncertain significance [VUS]) will cause FXI deficiency. Correlation with clinical history and factor XI activity is essential. (See <a class="local">'Evaluation'</a> below.)</p><p class="headingAnchor" id="H1237438025"><span class="h2"><i>F11 </i>genetics</span><span class="headingEndMark"> — </span>Over 400 distinct <em>F11</em> pathogenic variants have been reported, distributed throughout the gene [<a href="#rid2">2</a>]. They may affect the catalytic region of the enzyme or a homodimerization domain required for secretion. </p><p>Two <em>F11 </em>variants are highly represented in individuals of Ashkenazi (Eastern or Central European) Jewish ancestry with FXI deficiency (likely as founder mutations):</p><p class="bulletIndent1"><span class="glyph">●</span>Glu117Stop (E117X)</p><p class="bulletIndent1"><span class="glyph">●</span>Phe283Leu (F283L)</p><p></p><p>A less common variant in Ashkenazi Jewish individuals is c.1716+1G&gt;A.</p><p>Additional<em> </em>variants have been reported in certain groups [<a href="#rid3">3</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Cys38Arg (C38R) in French Basque people</p><p class="bulletIndent1"><span class="glyph">●</span>Gln88Stop (Q88X) in French people from Nantes</p><p class="bulletIndent1"><span class="glyph">●</span>Cys128Stop (C128X) in people from the United Kingdom</p><p class="bulletIndent1"><span class="glyph">●</span>Ile436Lys (I436K) in people from Northeastern Italy</p><p class="bulletIndent1"><span class="glyph">●</span>Gln263Stop (Q263X) in people of Korean descent </p><p></p><p>Inheritance may be autosomal recessive or dominant, depending on whether the variant reduces expression or creates an abnormal protein that interferes with function of the FXI produced from the normal<em> F11</em> allele. (See  <a class="medical medical_review" href="/z/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency", section on 'F11 gene variants'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Most variants that reduce protein expression show autosomal recessive inheritance. Homozygosity or compound heterozygosity is generally required for a clinical phenotype to manifest. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A few variants have been identified that act dominantly and show autosomal dominant inheritance. Heterozygotes are affected.</p><p></p><p>Genotype-phenotype relationships are complex. Some individuals with the same genotype may have significant differences in FXI activity [<a href="#rid4">4</a>]. Certain genotypes, especially those with severe FXI deficiency, such as homozygosity for E117X, are more likely to be associated with formation of inhibitors (alloantibodies) after exposure to exogenous FXI [<a href="#rid5">5,6</a>]. This information may guide care (avoiding FXI exposure in some settings, monitoring FXI activity more closely after treatment, and inhibitor testing). (See <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H997542925"><span class="h2">Factor XI deficiency</span></p><p class="headingAnchor" id="H3798702998"><span class="h3">Epidemiology</span><span class="headingEndMark"> — </span>Inherited FXI deficiency is rare, although the true prevalence is unknown [<a href="#rid7">7</a>]. Some individuals with FXI deficiency may never come to medical attention. (See  <a class="medical medical_review" href="/z/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency", section on 'Epidemiology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The estimated prevalence ranges from 1 in 1 million for symptomatic presentations to 1 in 1000 for asymptomatic individuals, depending upon the population. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FXI deficiency is more prevalent in individuals of Ashkenazi (Eastern and Central European) Jewish and Iraqi Jewish ancestry, with a carrier frequency as high as 8 to 9 percent (1 in 11 individuals). Biallelic deficiency variants (homozygosity or compound heterozygosity) may be seen in 1 in 450. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unlike hemophilia A and B, which are X-linked and predominantly affect males, transmission is autosomal (both sexes are affected equally). </p><p></p><p class="headingAnchor" id="H2057120294"><span class="h3">Bleeding risk</span><span class="headingEndMark"> — </span>FXI deficiency generally does not cause spontaneous bleeding (such as seen in severe hemophilia A or B), even with severely reduced FXI activity  (<a class="graphic graphic_table graphicRef130560" href="/z/d/graphic/130560.html" rel="external">table 3</a>). Bleeding in FXI deficiency is generally associated with injury, trauma, or an invasive procedure. Heavy menstrual bleeding may occur. (See  <a class="medical medical_review" href="/z/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency", section on 'Bleeding'</a>.)</p><p>The correlation between FXI activity and bleeding phenotype is weak; not all individuals with FXI deficiency have serious surgical or traumatic bleeding, and FXI activity levels cannot be used to predict bleeding risk. Individuals who did not bleed with prior trauma or surgery may experience bleeding in the future. Bleeding phenotype may be modified by:</p><p class="bulletIndent1"><span class="glyph">●</span>Surgery or injury to an area with increased fibrinolytic activity</p><p class="bulletIndent1"><span class="glyph">●</span>Other inherited disorders such as von Willebrand disease</p><p class="bulletIndent1"><span class="glyph">●</span>Medications that affect hemostasis such as <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a></p><p></p><p>Despite this variability, bleeding history remains important to assess symptoms that may require intervention such as heavy menstrual bleeding, to plan for upcoming interventions and pregnancy, and to ensure that patients, families, and caregivers have appropriate knowledge regarding optimal care. (See <a class="local">'Bleeding history'</a> below.)</p><p class="headingAnchor" id="H3791686098"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Evaluation for FXI deficiency requires review of the family history, information about Ashkenazi Jewish ancestry if available, personal bleeding history, and coagulation testing including FXI activity [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3358519883"><span class="h3">Bleeding history</span><span class="headingEndMark"> — </span>The bleeding history assesses any prior spontaneous bleeding or excessive bleeding with hemostatic challenges. It typically consists of questions that can be scored using a bleeding assessment tool (BAT). A BAT from the International Society of Thrombosis and Haemostasis is available online (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbleedingscore.certe.nl%2F&amp;token=Nn2kz6P9LalXZBakWq4EFVy%2FtKzfMxWmVZgnncoM9zqnY8WwoOfYCEf5tSBri%2Fvl&amp;TOPIC_ID=129854" target="_blank">ISTH-SSC BAT</a>) [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Bleeding score'</a>.) </p><p>Bleeding history is most useful for individuals who have experienced hemostatic challenges (trauma, surgery, dental procedures, pregnancies). It may be less useful in young children and adults without a prior history of injury or interventions. </p><p class="headingAnchor" id="H2768262311"><span class="h3">CBC and coagulation testing</span><span class="headingEndMark"> — </span>Any individual for whom there is concern about FXI deficiency (pathogenic variant in <em>F11</em>, positive family history, Ashkenazi Jewish ancestry) should undergo standard coagulation testing and an FXI activity level. </p><p>Initial testing (on a plasma sample) includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (CBC) with platelet count.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time (PT), activated thromboplastin time (aPTT), and fibrinogen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the PT and/or aPTT is prolonged, one to one mixing with normal plasma. Correction to the normal range indicates a factor deficiency. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Use of mixing studies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a factor deficiency is suspected, appropriate specific clotting factor levels such as FXI activity.</p><p></p><p>Typically, FXI deficiency results in a prolonged aPTT that corrects in a mixing study, normal PT, normal FVIII and FIX activity, and decreased FXI activity.</p><p>However, it is important to evaluate FXI activity in individuals with a strong suspicion for FXI deficiency regardless of the PT and aPTT results, as partial deficiency (FXI activity in the 20 to 60 percent range) and increased bleeding risk may be associated with a normal aPTT, depending on the laboratory and/or reagents used. </p><p>Normal FXI activity excludes FXI deficiency. Individuals with a positive bleeding history (or positive family history) should undergo evaluation for other potential causes. (See  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p class="headingAnchor" id="H669992041"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3076383395"><span class="h2">General recommendations</span><span class="headingEndMark"> — </span>The local hematologist provides coordinated care, supported by expert consultation with a hemophilia treatment center (HTC) or other center of excellence. The HTC or center of excellence will provide comprehensive evaluation and planning to assure optimal outcomes. Contact information is listed below. (See <a class="local">'Resources'</a> below.)</p><p>Management considerations are summarized in the table  (<a class="graphic graphic_table graphicRef130560" href="/z/d/graphic/130560.html" rel="external">table 3</a>). </p><p>Attention to the following is especially important:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Education</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Understanding of test results and implications (bleeding risk, inhibitor risk).</p><p class="bulletIndent2"><span class="glyph">•</span>Use of a medical alert bracelet and/or wallet card.</p><p class="bulletIndent2"><span class="glyph">•</span>Contact information for the primary hematologist, HTC, or center of excellence.</p><p class="bulletIndent2"><span class="glyph">•</span>Avoidance of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and nonsteroidal antiinflammatory drugs (NSAIDs) for routine pain or fever.</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counseling, including implications for first-degree relatives. (See <a class="local">'Considerations for relatives'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Planning</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Therapies for heavy menstrual bleeding</p><p class="bulletIndent2"><span class="glyph">•</span>Planning for elective surgery and pregnancy </p><p class="bulletIndent2"><span class="glyph">•</span>Inhibitor screening for selected individuals </p><p class="bulletIndent2"><span class="glyph">•</span>Consultation if an antiplatelet agent or anticoagulant is needed (eg, in atrial fibrillation) (see  <a class="medical medical_review" href="/z/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency", section on 'Anticoagulation or antiplatelet therapy'</a>) </p><p class="bulletIndent2"><span class="glyph">•</span>Preconception testing and counseling</p><p></p><p class="headingAnchor" id="H2364551657"><span class="h2">Surgery/invasive procedures</span><span class="headingEndMark"> — </span>The HTC or center of excellence should be consulted with sufficient notice to review the procedure and develop a plan for management that may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Use of antifibrinolytic therapy, plasma, FXI concentrate (not available in the United States), low dose recombinant activated factor VII (rFVIIa), or other hemostatic therapies [<a href="#rid10">10</a>]. These therapies may be given prophylactically, or they may be made available to be used if needed. Risks and benefits, including an increased risk of thrombosis, must be considered [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modifications to the procedure or anesthesia to reduce bleeding risk, or having the procedure performed at a different hospital with a dedicated HTC staff able to manage the patient should the need arise.</p><p></p><p class="headingAnchor" id="H3001217420"><span class="h2">Inhibitors</span><span class="headingEndMark"> — </span>Inhibitors are alloantibodies that develop in response to exogenous FXI exposure (from plasma transfusions or FXI concentrates). </p><p>These are rare [<a href="#rid12">12</a>]. However, they can occur with certain genotypes, especially those associated with severely reduced FXI activity. </p><p>In some individuals with a high risk of inhibitor development such as E117X homozygous individuals, consider avoiding plasma or FXI concentrates so that FXI concentrate can be reserved for life-threatening bleeding. (See <a class="local">'F11 genetics'</a> above.)</p><p>Inhibitors are suspected when bleeding does not respond to treatment with FXI or may be identified by screening in an at-risk individual. Those who develop an inhibitor may require other interventions. (See  <a class="medical medical_review" href="/z/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency", section on 'rFVIIa'</a>.)</p><p class="headingAnchor" id="H233284673"><span class="h2">Pregnancy and menstruation</span><span class="headingEndMark"> — </span>Females with known FXI deficiency or Ashkenazi Jewish ancestry should have testing and/or genetic counseling prior to conception, including FXI activity and the option of <em>F11</em> genetic testing. Paternal testing may be indicated.</p><p>Bleeding during pregnancy is variable in individuals with FXI deficiency; however, the risk of postpartum hemorrhage is increased; this risk may affect management of delivery, planning for neuraxial anesthesia, and postpartum treatment and monitoring  (<a class="graphic graphic_algorithm graphicRef119350" href="/z/d/graphic/119350.html" rel="external">algorithm 1</a>). Pregnancy and delivery should be managed in consultation with an HTC or center of excellence [<a href="#rid13">13,14</a>]. (See <a class="local">'Resources'</a> below.)</p><p>Individuals with heavy menstrual bleeding may benefit from taking an antifibrinolytic agent during the first few days of the menstrual cycle or using hormonal suppressive therapy. (See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p class="headingAnchor" id="H2648469549"><span class="h1">CONSIDERATIONS FOR RELATIVES</span><span class="headingEndMark"> — </span>All first-degree relatives of an individual with FXI deficiency are candidates for an evaluation that includes bleeding history, coagulation testing, FXI activity, and genetic testing and counseling. The hemophilia treatment center (HTC) or center of excellence can facilitate and coordinate this evaluation. (See <a class="local">'Resources'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>First-degree relatives of individuals who are heterozygous for a pathogenic variant in <em>F11</em> have a 1 in 2 chance of also being heterozygotes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Full siblings of individuals with biallelic pathogenic variants in <em>F11</em> (homozygous or compound heterozygous) have a 1 in 4 chance of carrying biallelic variants and a 1 in 2 chance of carrying a variant on one <em>F11</em> allele (being heterozygous).</p><p></p><p class="headingAnchor" id="H4038368417"><span class="h1">RESOURCES</span></p><p class="bulletIndent1"><span class="glyph">●</span>UpToDate topics</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FXI deficiency – (See  <a class="medical medical_review" href="/z/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bleeding disorder evaluation – (See  <a class="medical medical_review" href="/z/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms"</a> and  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a> and  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetics concepts – (See  <a class="medical medical_review" href="/z/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)"</a> and  <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a> and  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a> and  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetics professionals</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=129854" target="_blank">NSGC</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=129854" target="_blank">ACMG</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemophilia resources</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>World Federation of Hemophilia (WFH) – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwfh.org%2Ffind-local-support%2F&amp;token=Ppe7MR2Y7mkWqvWU%2FvbBSksfAAqo3clecpJFYQExDK1LnBEpuw5FPvoO5HA4D9E8&amp;TOPIC_ID=129854" target="_blank">Global Treatment Centre Directory</a> </p><p class="bulletIndent2"><span class="glyph">•</span>Centers for Disease Control and Prevention (CDC) in the United States – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdbdgateway.cdc.gov%2FHTCDirSearch.aspx&amp;token=1mlbwnMpT7N3%2F4R%2FWqdzPELkvXjFiKf%2FyIrok0FunpJwg9nlFe88ih%2F6PkDiz4qjmRYjW010hAgjRmYRRL4zFA%3D%3D&amp;TOPIC_ID=129854" target="_blank">HTC Directory</a></p><p class="bulletIndent2"><span class="glyph">•</span>National Hemophilia Foundation (NHF) in the United States – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hemophilia.org%2F&amp;token=sL%2Bp%2BgWoM5K8OZ3TcR7z2ZRp%2F9UOOya9Y7YI8CU%2BpsF5jI%2FfAp56Pqh%2FgQyP0%2FRt&amp;TOPIC_ID=129854" target="_blank">Resources</a></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li class="breakAll">Factor XI Gene (F11) Variant Database. The European Association for Haemophilia and Allied Disorders (EAHAD). Available at: https://f11-db.eahad.org/ (Accessed on February 27, 2023).</li><li><a class="nounderline abstract_t">Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost 2013; 39:621.</a></li><li><a class="nounderline abstract_t">Saunders RE, O'Connell NM, Lee CA, et al. Factor XI deficiency database: an interactive web database of mutations, phenotypes, and structural analysis tools. Hum Mutat 2005; 26:192.</a></li><li><a class="nounderline abstract_t">Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101:4783.</a></li><li><a class="nounderline abstract_t">O'Connell NM. Factor XI deficiency--from molecular genetics to clinical management. Blood Coagul Fibrinolysis 2003; 14 Suppl 1:S59.</a></li><li><a class="nounderline abstract_t">Zhang X, Lewandowska M, Aldridge M, et al. Global epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports. Haemophilia 2023; 29:423.</a></li><li><a class="nounderline abstract_t">Bertaggia Calderara D, Zermatten MG, Aliotta A, Alberio L. How to Capture the Bleeding Phenotype in FXI-Deficient Patients. Hamostaseologie 2020; 40:491.</a></li><li class="breakAll">https://bleedingscore.certe.nl/ (Accessed on October 22, 2020).</li><li><a class="nounderline abstract_t">Salomon O, Budnik I, Avishai E, et al. Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery. Thromb Haemost 2019; 119:1927.</a></li><li><a class="nounderline abstract_t">Bolton-Maggs P, Goudemand J, Hermans C, et al. FXI concentrate use and risk of thrombosis. Haemophilia 2014; 20:e349.</a></li><li><a class="nounderline abstract_t">Livnat T, Tamarin I, Mor Y, et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009; 102:487.</a></li><li><a class="nounderline abstract_t">Davies J, Kadir R. The Management of Factor XI Deficiency in Pregnancy. Semin Thromb Hemost 2016; 42:732.</a></li><li><a class="nounderline abstract_t">Wheeler AP, Hemingway C, Gailani D. The clinical management of factor XI deficiency in pregnant women. Expert Rev Hematol 2020; 13:719.</a></li></ol></div><div id="topicVersionRevision">Topic 129854 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://f11-db.eahad.org/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Factor XI Gene (F11) Variant Database. The European Association for Haemophilia and Allied Disorders (EAHAD). Available at: https://f11-db.eahad.org/ (Accessed on February 27, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23929304" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Congenital factor XI deficiency: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16086308" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Factor XI deficiency database: an interactive web database of mutations, phenotypes, and structural analysis tools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12586617" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14567539" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Factor XI deficiency--from molecular genetics to clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36367760" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Global epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33003209" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : How to Capture the Bleeding Phenotype in FXI-Deficient Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33003209" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : How to Capture the Bleeding Phenotype in FXI-Deficient Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31493780" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24785157" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : FXI concentrate use and risk of thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19718468" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27699729" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Management of Factor XI Deficiency in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32437625" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The clinical management of factor XI deficiency in pregnant women.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
